TEM screens as a clean technical entry. Price is holding above the Kijun, the forward cloud is twisting from red to green, and momentum is confirming rather than stretched: RSI near 58 is rising with room before overbought, and MACD has turned positive.
The honest caveat is that the breakout above the multi-month consolidation has already triggered, so the easy near-term pop is largely behind it. This is an early-breakout entry, not a coiled-spring setup — which argues for patience on execution.
A better entry likely comes on weakness: a retest back toward the $52–53 breakout zone would offer more favorable risk/reward than paying up at $56.
The runway is structural and layered. The higher-probability near-term move is a reversion up to the 200-day moving average — the first overhead magnet — before more significant resistance comes into play. Beyond that, Wall Street consensus sits in the high-$60s to low-$70s (24-analyst average ~$72) against a current $56, leaving meaningful upside if the AI-targeted healthcare thesis plays out over the intermediate term
The honest caveat is that the breakout above the multi-month consolidation has already triggered, so the easy near-term pop is largely behind it. This is an early-breakout entry, not a coiled-spring setup — which argues for patience on execution.
A better entry likely comes on weakness: a retest back toward the $52–53 breakout zone would offer more favorable risk/reward than paying up at $56.
The runway is structural and layered. The higher-probability near-term move is a reversion up to the 200-day moving average — the first overhead magnet — before more significant resistance comes into play. Beyond that, Wall Street consensus sits in the high-$60s to low-$70s (24-analyst average ~$72) against a current $56, leaving meaningful upside if the AI-targeted healthcare thesis plays out over the intermediate term
כתב ויתור
המידע והפרסומים אינם מיועדים להיות, ואינם מהווים, ייעוץ או המלצה פיננסית, השקעתית, מסחרית או מכל סוג אחר המסופקת או מאושרת על ידי TradingView. קרא עוד ב־תנאי השימוש.
כתב ויתור
המידע והפרסומים אינם מיועדים להיות, ואינם מהווים, ייעוץ או המלצה פיננסית, השקעתית, מסחרית או מכל סוג אחר המסופקת או מאושרת על ידי TradingView. קרא עוד ב־תנאי השימוש.